First human test of experimental cancer therapy begins
NCT ID NCT07159828
Summary
This early-stage study is testing a new drug called AXN-2510 in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the safest dose, understand side effects, and see how long the drug stays in the body. Participants receive the drug every three weeks and undergo regular monitoring and tests.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Carolina BioOncology
Huntersville, North Carolina, 28078, United States
-
NEXT Houston
Houston, Texas, 77054, United States
-
NEXT San Antonio
San Antonio, Texas, 78229, United States
-
NEXT Virginia
Fairfax, Virginia, 22031, United States
-
New Experimental Therapeutics (NEXT) Oncology - Houston
Houston, Texas, 77054, United States
-
New Experimental Therapeutics of San Antonio - NEXT Oncology
San Antonio, Texas, 78229, United States
-
Sarah Cannon Research Institute at Mary Crowley
Dallas, Texas, 75251, United States
Conditions
Explore the condition pages connected to this study.